Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

How Do the Virulence Factors of Shigella Work Together to Cause Disease?

Mattock E, Blocker AJ.

Front Cell Infect Microbiol. 2017 Mar 24;7:64. doi: 10.3389/fcimb.2017.00064. eCollection 2017. Review.

2.

The Type III Effector NleD from Enteropathogenic Escherichia coli Differentiates between Host Substrates p38 and JNK.

Creuzburg K, Giogha C, Wong Fok Lung T, Scott NE, Mühlen S, Hartland EL, Pearson JS.

Infect Immun. 2017 Jan 26;85(2). pii: e00620-16. doi: 10.1128/IAI.00620-16. Print 2017 Feb.

3.

Identification of a Distinct Substrate-binding Domain in the Bacterial Cysteine Methyltransferase Effectors NleE and OspZ.

Zhang Y, Mühlen S, Oates CV, Pearson JS, Hartland EL.

J Biol Chem. 2016 Sep 16;291(38):20149-62. doi: 10.1074/jbc.M116.734079. Epub 2016 Jul 21.

4.

Detection of enteric pathogens by the nodosome.

Keestra AM, Bäumler AJ.

Trends Immunol. 2014 Mar;35(3):123-30. doi: 10.1016/j.it.2013.10.009. Epub 2013 Nov 22. Review.

5.

A type III effector antagonizes death receptor signalling during bacterial gut infection.

Pearson JS, Giogha C, Ong SY, Kennedy CL, Kelly M, Robinson KS, Lung TW, Mansell A, Riedmaier P, Oates CV, Zaid A, Mühlen S, Crepin VF, Marches O, Ang CS, Williamson NA, O'Reilly LA, Bankovacki A, Nachbur U, Infusini G, Webb AI, Silke J, Strasser A, Frankel G, Hartland EL.

Nature. 2013 Sep 12;501(7466):247-51. doi: 10.1038/nature12524.

6.

Pathogenesis of human enterovirulent bacteria: lessons from cultured, fully differentiated human colon cancer cell lines.

Liévin-Le Moal V, Servin AL.

Microbiol Mol Biol Rev. 2013 Sep;77(3):380-439. doi: 10.1128/MMBR.00064-12. Review.

7.

Characterization of the ospZ promoter in Shigella flexneri and its regulation by VirB and H-NS.

Basta DW, Pew KL, Immak JA, Park HS, Picker MA, Wigley AF, Hensley CT, Pearson JS, Hartland EL, Wing HJ.

J Bacteriol. 2013 Jun;195(11):2562-72. doi: 10.1128/JB.00212-13. Epub 2013 Mar 29.

8.

A distinct regulatory sequence is essential for the expression of a subset of nle genes in attaching and effacing Escherichia coli.

García-Angulo VA, Martínez-Santos VI, Villaseñor T, Santana FJ, Huerta-Saquero A, Martínez LC, Jiménez R, Lara-Ochoa C, Téllez-Sosa J, Bustamante VH, Puente JL.

J Bacteriol. 2012 Oct;194(20):5589-603. Epub 2012 Aug 17.

9.

Always one step ahead: How pathogenic bacteria use the type III secretion system to manipulate the intestinal mucosal immune system.

Vossenkämper A, Macdonald TT, Marchès O.

J Inflamm (Lond). 2011 May 3;8:11. doi: 10.1186/1476-9255-8-11.

10.

Fecal leukocytes in children infected with diarrheagenic Escherichia coli.

Mercado EH, Ochoa TJ, Ecker L, Cabello M, Durand D, Barletta F, Molina M, Gil AI, Huicho L, Lanata CF, Cleary TG.

J Clin Microbiol. 2011 Apr;49(4):1376-81. doi: 10.1128/JCM.02199-10. Epub 2011 Feb 16.

11.

The type III effectors NleE and NleB from enteropathogenic E. coli and OspZ from Shigella block nuclear translocation of NF-kappaB p65.

Newton HJ, Pearson JS, Badea L, Kelly M, Lucas M, Holloway G, Wagstaff KM, Dunstone MA, Sloan J, Whisstock JC, Kaper JB, Robins-Browne RM, Jans DA, Frankel G, Phillips AD, Coulson BS, Hartland EL.

PLoS Pathog. 2010 May 13;6(5):e1000898. doi: 10.1371/journal.ppat.1000898.

12.

Prevalence and characteristics of the O122 pathogenicity island in typical and atypical enteropathogenic Escherichia coli strains.

Vieira MA, Salvador FA, Silva RM, Irino K, Vaz TM, Rockstroh AC, Guth BE, Gomes TA.

J Clin Microbiol. 2010 Apr;48(4):1452-5. doi: 10.1128/JCM.01944-09. Epub 2010 Feb 24.

13.

The type III secretion effector NleE inhibits NF-kappaB activation.

Nadler C, Baruch K, Kobi S, Mills E, Haviv G, Farago M, Alkalay I, Bartfeld S, Meyer TF, Ben-Neriah Y, Rosenshine I.

PLoS Pathog. 2010 Jan 29;6(1):e1000743. doi: 10.1371/journal.ppat.1000743.

14.

The role of neutrophils in the event of intestinal inflammation.

Mumy KL, McCormick BA.

Curr Opin Pharmacol. 2009 Dec;9(6):697-701. doi: 10.1016/j.coph.2009.10.004. Epub 2009 Oct 24. Review.

15.

The Shigella dysenteriae serotype 1 proteome, profiled in the host intestinal environment, reveals major metabolic modifications and increased expression of invasive proteins.

Pieper R, Zhang Q, Parmar PP, Huang ST, Clark DJ, Alami H, Donohue-Rolfe A, Fleischmann RD, Peterson SN, Tzipori S.

Proteomics. 2009 Nov;9(22):5029-45. doi: 10.1002/pmic.200900196.

16.

The effector repertoire of enteropathogenic E. coli: ganging up on the host cell.

Dean P, Kenny B.

Curr Opin Microbiol. 2009 Feb;12(1):101-9. doi: 10.1016/j.mib.2008.11.006. Epub 2009 Jan 12. Review.

17.

Shigella flexneri type III secretion system effectors OspB and OspF target the nucleus to downregulate the host inflammatory response via interactions with retinoblastoma protein.

Zurawski DV, Mumy KL, Faherty CS, McCormick BA, Maurelli AT.

Mol Microbiol. 2009 Jan;71(2):350-68. doi: 10.1111/j.1365-2958.2008.06524.x. Epub 2008 Nov 14.

18.

Distinct isoforms of phospholipase A2 mediate the ability of Salmonella enterica serotype typhimurium and Shigella flexneri to induce the transepithelial migration of neutrophils.

Mumy KL, Bien JD, Pazos MA, Gronert K, Hurley BP, McCormick BA.

Infect Immun. 2008 Aug;76(8):3614-27. doi: 10.1128/IAI.00407-08. Epub 2008 May 27.

Supplemental Content

Support Center